Authors: Hibiki Udagawa Seiji Niho Keisuke Kirita Shigeki Umemura Shingo Matsumoto Kiyotaka Yoh Koichi Goto
Publish Date: 2017/02/20
Volume: 143, Issue: 6, Pages: 1075-1082
Abstract
Denosumab reduces the incidence of skeletalrelated events SREs in solid tumor patients with bone metastases BM However there have been no detailed reports of the efficacy of denosumab in untreated nonsquamous nonsmall cell lung cancer NSCLC patients with BMOf the total of 149 patients who were eligible 52 had received denosumab Dmab group 51 had received zoledronic acid ZA group and 46 had received no treatment NoTx group for the BM The frequencies of prior SREs were higher in the Dmab group and ZA group than in the NoTx group 44 41 and 22 respectively however there were no significant differences in any of the other clinicopathological characteristics examined among the three groups The median OS in the Dmab group ZA group and NoTx group were 214 months 127 months and 105 months respectively the OS was significantly longer in the Dmab group than in the ZA group P 001 Results of multivariate analysis revealed that denosumab treatment was significantly associated with a more favorable survival hazard ratio 0500 95 CI 0332–0741 P 001 No significant difference in the time to SREs was observed among the three groupsAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards
Keywords: